About Us

http://www.treatoa.eu/wp-content/uploads/2013/08/aboutus_featured_img.jpg

TREAT-OA is a large-scale collaborative, integrated, trans-disciplinary project to address the need for better treatment and diagnostics for osteoarthritis, the most common cause of disability in Europe. The consortium members are worldclass expert investigators from the US, Asia and Europe who will contribute to TREAT-OA biospecimens and clinical data from their own cohorts.

The gene driven approach aims to provide new therapeutic targets as well as tools to select patients which will be most likely to respond to those therapies effectively. It will also deliver a comprehensive technology platform with a focus on gaining new insights into the development and progression of human OA. The goal is to identify diagnostic and prognostic genetic markers for disease risk and progression and potential therapeutic targets. Currently there are no drugs that can cure, reverse or halt the disease. Nor are there yet reliable clinical biochemical markers for diagnosis or prognosis which is an impediment to the management of OA, the development of disease modifying drugs and increases the cost of therapeutic trials.This is the largest study of its kind that will address the generalisability and utility of genetic and biochemical risk factors throughout the EU and establish animal models for OA, which will help in further elucidating the pathogenetic mechanisms and also in the evaluation of intervention strategies that will be aimed at delaying the onset of the disease and in improving the quality of life.


The key objectives of TREAT-OA are to:

1. Identify genes and biochemical markers consistently associated with risk and progression of OA.
2. Define the roles of these genes to further our understanding of the molecular pathways involved in disease aetiology.
3. Analyze the molecular pathways to identify targets for pharmacological intervention.
4. Develop in vivo models by the use of transgenic animal laboratory OA model systems.
5. Develop a panel of genetic and biochemical diagnostics for risk and progression of OA.
6. Disseminate results to the scientific community and use results and technologies for training within the EU TREAT-OA will help develop European clinical and scientific excellence in the diagnosis and treatment of OA.

The novel pathways in disease aetiology discovered will translate into novel drug targets and protein therapeutics for OA. The development of in vitro and in vivo assays will provide a comprehensive technology platform enabling the discovery and development of disease modifying drugs for OA. TREAT-OA will also make a major impact on the disease via a diagnostic panel of genes and biochemical markers for selecting severe cases and individuals who will experience rapid progression of their disease.

Download a poster about TreatOA

Download a brochure about TreatOA

TREAT-OA is a large-scale collaborative, integrated, trans-disciplinary project to address the need for better treatment and diagnostics for osteoarthritis, the most common cause of disability in Europe. The consortium members are worldclass expert investigators from the US, Asia and Europe who will contribute to TREAT-OA biospecimens and clinical data from their own cohorts.

The gene driven approach aims to provide new therapeutic targets as well as tools to select patients which will be most likely to respond to those therapies effectively. It will also deliver a comprehensive technology platform with a focus on gaining new insights into the development and
progression of human OA. The goal is to identify diagnostic and prognostic genetic markers for disease risk and progression and potential therapeutic targets. Currently there are no drugs that can cure, reverse or halt the disease. Nor are there yet reliable clinical biochemical markers for diagnosis or prognosis which is an impediment to the management of OA, the development of disease modifying drugs and increases the cost of therapeutic trials.This is the largest study of its kind that will address the generalisability and utility of genetic and biochemical risk factors throughout the EU and establish animal models for OA, which will help in further elucidating the pathogenetic mechanisms and also in the evaluation of intervention strategies that will be aimed at delaying the onset of the disease and in improving the quality of life. The novel pathways in disease aetiology discovered will translate into novel drug targets and protein therapeutics for OA. The development of in vitro and in vivo assays will provide a comprehensive technology platform enabling the discovery and development of disease modifying drugs for OA. TREAT-OA will also make a major impact on the disease via a diagnostic panel of genes and biochemical markers for selecting severe cases and individuals who will experience rapid progression of their disease.